logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.

    Article - En anglais

    Background and Methods Use of nicotine-replacement therapies and the antidepressant bupropion helps people stop smoking.

    We conducted a double-blind, placebo-controlled comparison of sustained-release bupropion (244 subjects), a nicotine patch (244 subjects), bupropion and a nicotine patch (245 subjects), and placebo (160 subjects) for smoking cessation.

    Smokers with clinical depression were excluded.

    Treatment consisted of nine weeks of bupropion (150 mg a day for the first three days, and then 150 mg twice daily) or placebo, as well as eight weeks of nicotine-patch therapy (21 mg per day during weeks 2 through 7,14 mg per day during week 8, and 7 mg per day during week 9) or placebo.

    The target day for quitting smoking was usually day 8. Results The abstinence rates at 12 months were 15.6 percent in the placebo group, as compared with 16.4 percent in the nicotine-patch group, 30.3 percent in the bupropion group (P<0.001), and 35.5 percent in the group given bupropion and the nicotine patch (P<0.001).

    By week 7, subjects in the placebo group had gained an average of 2.1 kg, as compared with a gain of 1.6 kg in the nicotine-patch group, a gain of 1.7 kg in the bupropion group, and a gain of 1.1 kg in the combined-treatment group (P<0.05).

    Weight gain at seven weeks was significantly less in the combined-treatment group than in the bupropion group and the placebo group (P<0.05 for both comparisons).

    A total of 311 subjects (34.

    (...)

    Mots-clés Pascal : Tabagisme, Sevrage, Essai clinique, Amfébutamone, Nicotine, Patch, Base donnée répartie, Analyse statistique, Efficacité traitement, Long terme, Placebo, Homme, Etats Unis, Amérique du Nord, Amérique, Toxicomanie, Antidépresseur, Psychotrope, Informatique, Statistique

    Mots-clés Pascal anglais : Tobacco smoking, Weaning, Clinical trial, Amfebutamone, Nicotine, Patch, Distributed database, Statistical analysis, Treatment efficiency, Long term, Placebo, Human, United States, North America, America, Drug addiction, Antidepressant agent, Psychotropic, Computer science, Statistics

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0180189

    Code Inist : 002B03E. Création : 16/11/1999.